Related Experiment Video
Updated: Oct 5, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
Purinergic signaling elements are correlated with coagulation players in peripheral blood and leukocyte samples from
Iago C Schultz1, Ana Paula S Bertoni1, Márcia R Wink2
1Departamento de Ciências Básicas da Saúde, Laboratório de Biologia Celular, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite, 245 Sala 304, Porto Alegre, RS, 90050-170, Brazil.
Insights
COVID-19 patients show altered adenosinergic pathways in leukocytes, with increased inosine and nucleotides like ATP and ADP correlating with coagulation factors. Targeting these molecules may reduce inflammation and coagulopathy.
Area of Science:
- Biochemistry
- Immunology
- Virology
Background:
- Coronavirus disease 2019 (COVID-19) causes severe tissue injury, inflammation, and coagulopathy.
- Extracellular adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD+) are released during infection and cell death.
- These molecules play key roles in purinergic signaling pathways.
Purpose of the Study:
- To compare the purinergic profile of leukocytes in COVID-19 patients versus healthy or non-COVID-19 individuals.
- To evaluate blood levels of soluble biomolecules and their correlation with coagulation components in COVID-19.
- To analyze leukocyte gene expression related to purinergic and adenosinergic pathways.
Main Methods:
- Analysis of public Gene Expression Omnibus (GEO) datasets, including proteomics (mass spectrometry) and genomics (microarray) data.
- Bioinformatic and statistical analysis of COVID-19 patient samples and controls.
- Blood metabolite analysis and leukocyte gene expression profiling.
Main Results:
- COVID-19 patients exhibited a stage-dependent increase in blood inosine levels.
- ATP and ADP showed positive correlations with fibrinogen and other coagulation proteins.
- Upregulation of P2 receptors (P2RX1, P2RX4, P2RX5, P2RX7, P2RY1, P2RY12), PANX1, ADORA2B, NLPR3, and F3 genes in leukocytes was observed.
- Ectoenzymes ENTPD1 and CD38 were upregulated, indicating active adenosine production.
Conclusions:
- Adenosinergic pathways are significantly modulated in leukocytes of COVID-19 patients.
- Elevated plasma inosine and correlations between nucleotides (ATP, ADP) and coagulation factors highlight their involvement in COVID-19 pathophysiology.
- Targeting these purinergic molecules, receptors, or ectoenzymes presents a potential therapeutic strategy for mitigating COVID-19-associated inflammation and coagulopathy.
Abstract:
For over a year, the coronavirus disease 2019 has been affecting the world population by causing severe tissue injuries and death in infected people. Adenosine triphosphate (ATP) and the nicotinamide adenine dinucleotide (NAD +) are two molecules that are released into the extracellular microenvironment after direct virus infection or cell death caused by hyper inflammation and coagulopathy. Also, these molecules are well known to participate in multiple pathways and have a pivotal role in the purinergic signaling pathway. Thus, using public datasets available on the Gene Expression Omnibus (GEO), we analyzed raw proteomics data acquired using mass spectrometry (the gold standard method) and raw genomics data from COVID-19 patient samples obtained by microarray. The data was analyzed using bioinformatics and statistical methods according to our objectives. Here, we compared the purinergic profile of the total leukocyte population and evaluated the levels of these soluble biomolecules in the blood, and their correlation with coagulation components in COVID-19 patients, in comparison to healthy people or non-COVID-19 patients. The blood metabolite analysis showed a stage-dependent inosine increase in COVID-19 patients, while the nucleotides ATP and ADP had positive correlations with fibrinogen and other coagulation proteins. Also, ATP, ADP, inosine, and hypoxanthine had positive and negative correlations with clinical features. Regarding leukocyte gene expression, COVID-19 patients showed an upregulation of the P2RX1, P2RX4, P2RX5, P2RX7, P2RY1, P2RY12, PANX1, ADORA2B, NLPR3, and F3 genes. Yet, the ectoenzymes of the canonical and non-canonical adenosinergic pathway (ENTPD1 and CD38) are upregulated, suggesting that adenosine is produced by both active adenosinergic pathways. Hence, approaches targeting these biomolecules or their specific purinoreceptors and ectoenzymes may attenuate the high inflammatory state and the coagulopathy seen in COVID-19 patients. KEY MESSAGES : Adenosinergic pathways are modulated on leukocytes from COVID-19 patients. Plasmatic inosine levels are increased in COVID-19 patients. ATP, ADP, AMP, hypoxanthine, and inosine are correlated with coagulation players. The nucleotides and nucleosides are correlated with patients' clinical features. The P2 receptors and ectoenzymes are correlated with Tissue factor in COVID-19.
More Related Videos
Related Concept Videos
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

